Asia Pacific Fabry Disease Treatment Market Size & Outlook
Asia Pacific fabry disease treatment market, 2016-2027 (US$M)
Related Markets
Asia Pacific fabry disease treatment market highlights
- The Asia Pacific fabry disease treatment market generated a revenue of USD 114.3 million in 2020.
- The market is expected to grow at a CAGR of 3.2% from 2021 to 2027.
- In terms of segment, replagal was the largest revenue generating product in 2020.
- Galafold is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Australia is expected to register the highest CAGR from 2021 to 2027.
Asia Pacific data book summary
| Market revenue in 2020 | USD 114.3 million |
| Market revenue in 2027 | USD 142.5 million |
| Growth rate | 3.2% (CAGR from 2020 to 2027) |
| Largest segment | Replagal |
| Fastest growing segment | Galafold |
| Historical data covered | 2016 - 2019 |
| Base year for estimation | 2020 |
| Forecast period covered | 2021 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Galafold, Fabrazyme, Replagal |
| Key market players worldwide | 3D Systems Corp, Formlabs, Voxeljet AG ADR |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 9.5% of the global fabry disease treatment market in 2020.
- Globally, North America is projected to lead the regional market in terms of revenue in 2027.
- MEA is the fastest growing regional market and is projected to reach USD 21.0 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Fabry Disease Treatment Market Scope
Fabry Disease Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific fabry disease treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to fabry disease treatment market will help companies and investors design strategic landscapes.
Replagal was the largest segment with a revenue share of 62.12% in 2020. Horizon Databook has segmented the Asia Pacific fabry disease treatment market based on galafold, fabrazyme, replagal covering the revenue growth of each sub-segment from 2016 to 2027.
Fabry Disease is included in the Specified Disease Treatment Research Program in Japan. The program subsidizes medical care for beneficiaries with rare and designated diseases.
An article published in the Journal of Epidemiology has analyzed the clinical research data reports submitted to the program between 2003 and 2008 and estimated the incidence of Fabry Disease in Japan as 0.25 per 100,000 population.
According to the Clinical features and genetic analysis of a Chinese kindred with Fabry’s disease published by Nephrology Dialysis Transplantation, Fabry's disease is a rare but recognized disease in China, which can present with cardiovascular, kidney, or cutaneous manifestations.
Reasons to subscribe to Asia Pacific fabry disease treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific fabry disease treatment market databook
-
Our clientele includes a mix of fabry disease treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific fabry disease treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific fabry disease treatment market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific fabry disease treatment market size, by country, 2016-2027 (US$M)
Asia Pacific Fabry Disease Treatment Market Outlook Share, 2020 & 2027 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
